Descripción de la empresa
InMed Pharmaceuticals Inc. operates as a clinical stage pharmaceutical entity dedicated to developing a pipeline of prescription-based products within the United States market. The organization functions through two distinct segments, specifically InMed Pharmaceuticals and BayMedica Commercial, with the former focusing on research and development efforts related to cannabino-related products. This enterprise is categorized within the Healthcare sector, specifically functioning in the Drug Manufacturers - Specialty & Generic industry, which denotes a focus on specialized therapeutic compounds rather than mass-market generic pharmaceuticals. The company currently maintains a market capitalization of $1.99M and generates annual revenue of $4.51M while employing a workforce of 13 individuals. These financial figures indicate that InMed Pharmaceuticals is a micro-cap entity with minimal operational scale, reflecting its status as a pre-revenue or early-stage development company where limited capitalization is typical for firms heavily invested in research activities before achieving commercial profitability.
Salud financiera
The company reported a trailing twelve-month revenue of $4.51M, yet this generated a net income loss of $-7,664,363, revealing a significant gap that points to substantial operating expenses, likely driven by research and development costs that exceed current sales volume. The enterprise also recorded an EBITDA of $-7,630,413, which further highlights the heavy burn rate associated with maintaining a clinical stage pipeline without established commercial revenue streams to offset costs. Despite these losses, the company holds a cash balance of $7.00M, providing a temporary buffer against its negative free cash flow of $-4,306,249, though this outflow limits immediate financial flexibility and operational runway. Profitability metrics are severely impacted, with a gross margin of 29.7% indicating that production costs consume a portion of revenue, but the operating margin stands at -258.6% and profit margin at -170.1%, confirming that overhead and R&D expenses drastically erode earnings before interest and taxes. The balance sheet shows a debt obligation of $531,949 against total cash reserves of $7.00M, resulting in a debt-to-equity ratio of 5.55, which suggests a highly leveraged position relative to equity despite the absolute debt being low in nominal terms. Liquidity appears robust on a short-term basis, evidenced by a current ratio of 5.94, indicating that current assets are more than five times current liabilities. However, return metrics reflect the negative equity position, with a return on equity of -97.2% and a return on assets of -49.8%, demonstrating that management has not yet generated positive returns on the capital deployed or assets held.
Evaluación de valoración
Valuation multiples present a complex picture for this loss-making entity, as the trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed at -0.11, implying that analysts do not anticipate positive earnings in the immediate future to justify a traditional multiple. The price-to-book ratio is 0.20, suggesting that the market values the company at significantly less than its net asset book value, which is common for distressed or pre-profitability firms but indicates a lack of market premium over tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 0.44 and an EV/EBITDA of 0.59 are utilized to assess value when earnings are negative, indicating that investors are pricing the company primarily on revenue generation potential rather than current profitability. The stock has exhibited significant volatility, trading between a 52-week high of $7.98 and a 52-week low of $0.57, meaning the current valuation sits within a wide range that reflects speculative pricing typical of small-cap biotech stocks. The beta value is 0.52, which indicates that the stock's price volatility is approximately half that of the broader market, suggesting lower systematic risk compared to large-cap equities despite the inherent risks of the clinical stage business model.
Growth & Income
Revenue growth year-over-year stands at -26.2%, indicating a contraction in sales, while earnings growth is N/A due to the absence of profitable earnings in the current period. The decline in revenue suggests a challenge in scaling sales for the commercial segment or a reduction in product demand within the specific therapeutic areas targeted by the company. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate, as the payout ratio is 0.0% and all available earnings are theoretically reinvested into the business or retained to sustain operations. Consequently, the overall growth and income profile is characterized by negative revenue expansion and a complete absence of distributable income, relying entirely on the depletion of cash reserves to fund future product development and market entry strategies.